Edinburgh Clinical Trials


Diagnostic Accuracy Study Of A MALDI-MS Biomarker Of Acute Kidney Injury After Femoral Fracture Surgery

One fifth of the 70,000 UK patients that break their hip annually suffer a loss of kidney function (AKI). AKI can lead to a longer hospital stay, dialysis, and even death. Routine tests detect kidney injury at a late stage when treatment is ineffective. We plan to perform a multicentre clinical evaluation of a new test that identifies AKI early with the aim of reducing the severity and harm of AKI after hip fracture.


Chief Investigator: Dr David Griffith

Number and location of participating sites (by region/ country): UK 2

EudraCT number: N/A


Funder: Chief Scientist Office Scotland

Start and End date

Grant: 1 September 2018 to 29 February 2020

Recruitment: TBC



Current Status: Awaiting publication


Trial Unblinding Information: N/A


Contact details:

ACCORD https://www.accord.scot/

Chief Investigator: Dr David M Griffith, Anaesthesia, Critical Care and Pain, The University of Edinburgh, David.M.Griffith@ed.ac.uk

Trial manager: N/A

Research nurse: N/A


ECTU involvement: Statistics